Global Challenges with Oral Antivirals for COVID-19

Smith, Dallas J.; Hakim, Avi J.; Taylor, Andrea; Bennett, Sarah D.; Patel, Pragna; Greiner, Ashley; Marston, Barbara J.

doi:10.1089/pop.2022.0171

Advanced Search

Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

Advanced Search
Custom Query

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Global Challenges with Oral Antivirals for COVID-19

12 2022
By Smith, Dallas J. ; Hakim, Avi J. ; Taylor, Andrea ; ...
http://dx.doi.org/10.1089/pop.2022.0171
Source: Popul Health Manag. 25(6):822-827

[PDF-72.87 KB]

English

Details Supporting Files You May Also Like

Details:

Alternative Title:

Popul Health Manag
Personal Author:

Smith, Dallas J. ; Hakim, Avi J. ; Taylor, Andrea ; Bennett, Sarah D. ; Patel, Pragna ; ... More +

Smith, Dallas J. ; Hakim, Avi J. ; Taylor, Andrea ; Bennett, Sarah D. ; Patel, Pragna ; Greiner, Ashley ; Marston, Barbara J. Less -
Description:

Oral antivirals for COVID-19 can be game changers in low- and middle-income countries (LMICs). Challenges that may hinder current and future oral antiviral rollouts span use in special populations, drug-drug and herb-drug interactions, adverse events, development of resistance, black markets, and equity in access and prescribing. Future antivirals may address some of these barriers; however, health systems around the world should be equipped to receive and administer COVID-19 oral antivirals. Improvements in manufacturing capacity, community engagement, capacity for testing and linkage to care, and systems for surveillance and safety monitoring could "change the game" for LMICs, irrespective of any specific antiviral drug. Investments in health care infrastructure can promote resilience, not only for COVID-19 but also for future local and global health crises.
Keywords:

[+]

Antiviral Agents Antivirals COVID-19 Developing Countries Global Health Health Care Infrastructure Humans
Source:

Popul Health Manag. 25(6):822-827
Pubmed ID:

36315439
Pubmed Central ID:

PMC10894658
Document Type:

Journal Article
Funding:

CC999999/ImCDC/Intramural CDC HHSUnited States/
Volume:

25
Issue:

6
Collection(s):

CDC Public Access
Main Document Checksum:

[+]

urn:sha256:e3c1aa38636d5ca5c5e093eb4e7796f2f2b1bff660727fdb4382d57f969ef80f
Download URL:

https://stacks.cdc.gov/view/cdc/150337/cdc_150337_DS1.pdf
File Type:

nihms-1964270.nxml

xml

More +